FDA Panel To Review Ovation’s Sabril For Dual Epilepsy Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
Vigabatrin set for review by Peripheral and Central Nervous System Drugs panel for seizures in adults and infantile spasms Aug. 6-7.
You may also be interested in...
FDA Resolves Ovation Sabril Conflict Of Interest; Sets Jan. 7-8 Advisory Panel Meeting
Peripheral and CNS Drugs Advisory Committee to consider two indications for Sabril: to treat infantile spasms and as adjunctive therapy for refractory complex partial seizures in adults.
FDA Resolves Ovation Sabril Conflict Of Interest; Sets Jan. 7-8 Advisory Panel Meeting
Peripheral and CNS Drugs Advisory Committee to consider two indications for Sabril: to treat infantile spasms and as adjunctive therapy for refractory complex partial seizures in adults.
The Longest Review: Inside Ovation’s Wait For Sabril
The anticonvulsant vigabatrin is one of a dozen products for which FDA has missed user fee deadlines so far this year. Fifteen years after the NDA first was submitted, maybe that shouldn’t be a surprise.